Straits Times Index
3,310.84 +13.95 (+0.42%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,459.53 +252.40 (+1.39%) FTSE 100
8,172.15 +50.91 (+0.63%) Bitcoin USD
59,537.93 +2,109.36 (+3.67%) CMC Crypto 200
1,282.05 +5.08 (+0.40%)
STAAR Surgical Company (STAA)
After hours:
| Previous close | 44.69 |
| Open | 45.46 |
| Bid | 45.43 x 100 |
| Ask | 45.57 x 100 |
| Day's range | 44.38 - 45.78 |
| 52-week range | 26.66 - 68.27 |
| Volume | |
| Avg. volume | 720,127 |
| Market cap | 2.237B |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | 105.91 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
STAAR Surgical Company's (NASDAQ:STAA) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
STAAR Surgical (NASDAQ:STAA) has had a great run on the share market with its stock up by a significant 64% over the...
- Zacks
Strength Seen in Staar Surgical (STAA): Can Its 16.5% Jump Turn into More Strength?
Staar Surgical (STAA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Benzinga
Eye Lens Maker STAAR Surgical Expects Q1 Sales To Beat Consensus
Thursday, STAAR Surgical Company (NASDAQ:STAA) reported preliminary net sales for the first quarter of 2024 of more than $77 million versus the consensus of $72.13 million, with U.S. ICL sales expected to be $5 million for the quarter. This represents the company’s highest quarterly ICL sales in the U.S. since the company obtained U.S. FDA approval for the EVO ICL in March 2022. “STAAR is off to a solid start in 2024 as illustrated by our preliminary first quarter results, including a record qua
